Nakamura-Takahashi, A., Miyake, K., Watanabe, A., Hirai., Y., Iijima, O., Miyake, N., Adachi, K., Nitahara-Kasahara, Y., Kinoshita, H., Noguch, T., Abe, S., Narisawa, S., Millán, J.L., Shimada, T. and Okada, T. (2016) Treatment of Hypophospatasia by Muscle-Directed Expression of Bone-Targeted Alkaline Phosphatase via Self-Complementary AAV8 Vector. Molecular Therapy—Methods & Clinical Development, 3, Article 15059.
https://doi.org/10.1038/mtm.2015.59

has been cited by the following article:

• TITLE: Improvement of Bone and Dental Phenotype of Murine Hypophosphatasia Mediated by a Single Injection of Lentiviral Gene Therapy

  AUTHORS: Seiko Yamamoto-Nemoto, Kei Ogawa, Eri Yokoi, Kanako Sawamoto, Akane Yamaguchi, Elif Bahar Tuna, Takehiko Shimizu

  KEYWORDS: Hypophosphatasia, Odonto-HPP, Tissue Non-Specific Alkaline Phosphatase

  JOURNAL NAME: Open Journal of Stomatology, Vol.7 No.1, January 18, 2017

  ABSTRACT: Background: Alkaline phosphatase has 4 isozymes, tissue non-specific alkaline phosphatase (TNAP), placental alkaline phosphatase (PLAP), intestinal alkaline phosphatase and germ-cell alkaline phosphatase. Hypophosphatasia (HPP) is an inherited skeletal disease caused by mutations of the gene encoding TNAP. Although TNAP is expressed in various tissues, the primary HPP symptoms appear in bones and teeth. The clinical severity of HPP varies widely from the most severe (perinatal, infantile and childhood) to the mildest forms (adult, and odonto-hypophosphatasia). We reported that gene therapy using a single injection of lentiviral vector expressing bone-targeted TNAP (TNAP-D10) is effective in preventing all the skeletal of HPP in TNAP knockout (Alpl–/–) mice as the model of infantile HPP. Objective: In this study we focus on evaluating the efficacy of treatment with gene therapy on the bone and teeth using TNAP-D10 and also we investigate the feasibility of gene therapy using bone-targeted PLAP (PLAP-D10). Methods and Findings: We used Alpl–/–mice that develop skeletal disease at postnatal days 6-8 mimicking the infantile form of human HPP. We injected 100 μl of lentiviral vectors harboring TNALP-D10 (5.0 × 107 TU) or PLAP-D10 (5.0 × 107 TU) to 1-day-old Alpl–/–mice via the jugular vein. We performed histological analysis and micro-CT evaluation on bone and mandible of Alpl–/–mice. The alveolar bone, enamel and dentin defects were corrected on treated Alpl–/–mice by this treatment. Additionally the long bone growth rates (LGR) of long bones were encouraged on treated Alpl–/–mice compared with untreated mice. Conclusions: These results indicate that the bone-targeted TNAP treatment mediated by lentivirus can correct not only the bone disorder but also the dental symptoms in Alpl–/–. This study also shows that PLAP-D10 can potentially be used to correct HPP disease.